{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:23:52Z","timestamp":1787027032346,"version":"build-2736575974"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010751","name":"Fondo Nacional de Desarrollo Cient\u00edfico, Tecnol\u00f3gico y de Innovaci\u00f3n Tecnol\u00f3gica","doi-asserted-by":"publisher","award":["11240623"],"award-info":[{"award-number":["11240623"]}],"id":[{"id":"10.13039\/501100010751","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005916","name":"Universidad de La Frontera","doi-asserted-by":"publisher","award":["PP25-0007"],"award-info":[{"award-number":["PP25-0007"]}],"id":[{"id":"10.13039\/501100005916","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Breast cancer treatment remains a major challenge to modern medicine and has driven the need for nanotechnology-based strategies to improve drug delivery and overcome chemoresistance. Poly(ethylene glycol) and poly (lactic-co-glycolic acid) (PEG\u2013PLGA) nanoparticles (NPs) are a type of FDA-approved biodegradable copolymer (lactic + glycolic acids) that degrades into non-toxic metabolites (lactic acid and glycolic acid); it has emerged as a promising drug carrier owing to its biocompatibility, sustained release properties, and ability to enhance the cellular uptake of chemotherapeutic agents. This systematic review examines the efficacies of PEG\u2013PLGA nanoparticles loaded with antineoplastic drugs on\n                      <jats:italic>in vitro<\/jats:italic>\n                      models of breast cancer cell lines.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Following PRISMA guidelines, we conducted a comprehensive search of the Web of Science, Embase, MEDLINE, and Scopus databases to identify experimental studies published between 2014 and August 2025 that evaluated PEG\u2013PLGA formulations applied to breast cancer cell lines. The methodological quality of each study was appraised using the National Institute for Health and Care Excellence (NICE) criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirteen studies were chosen based on our inclusion criteria. Here, the PEG\u2013PLGA nanoparticles were predominantly spherical (30\u2013210\u00a0nm) and exhibited controlled release kinetics. Compared with free drugs, the nanoformulations significantly reduced cell viability, increased apoptosis, and induced cell-cycle arrest. Functionalization with ligands such as folic acid enhanced drug targeting and cytotoxicity, while the molecular analyses revealed upregulation of p53, Bax, and caspases as well as downregulation of\n                      <jats:italic>Bcl-2<\/jats:italic>\n                      and\n                      <jats:italic>hTERT<\/jats:italic>\n                      genes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      PEG\u2013PLGA nanoparticles can substantially improve the selectivity, bioavailability, and cytotoxic efficacies of anticancer drugs in breast cancer\n                      <jats:italic>in vitro<\/jats:italic>\n                      . These findings underscore their translational potential as next-generation drug-delivery systems, warranting\n                      <jats:italic>in vivo<\/jats:italic>\n                      validation as well as development of theranostic- and stimulus-responsive designs for personalized oncology.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251076570<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1710176","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T07:25:18Z","timestamp":1767597918000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Effectiveness of drug-loaded poly(ethylene glycol) and poly(lactic-co-glycolic-acid) nanoparticles in the in vitro treatment of breast cancer: a systematic review"],"prefix":"10.3389","volume":"16","author":[{"given":"Cristian","family":"Sandoval-V\u00e1squez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"C\u00e1rcamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Lagos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00eds","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Zavala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Colil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca","family":"Villagr\u00e1n-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"V\u00e1squez-Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Hernandez-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Vald\u00e9s-Badilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Torrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Fincheira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Sep\u00falveda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann. Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3322\/caac.21225","article-title":"Priorities for the primary prevention of breast cancer","volume":"64","author":"Colditz","year":"2014","journal-title":"CA Cancer J. Clin."},{"key":"B3","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","article-title":"PLGA-based nanoparticles: an overview of biomedical applications","volume":"161","author":"Danhier","year":"2012","journal-title":"J. Control. Release"},{"key":"B4","volume-title":"Breast imaging reporting and data system: ACR BI-RADS\u2014Breast imaging Atlas","author":"D\u2019Orsi","year":"2013"},{"key":"B5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ijpharm.2016.11.012","article-title":"Folic acid-decorated and PEGylated PLGA nanoparticles for improving the antitumour activity of 5-fluorouracil","volume":"516","author":"El-Hammadi","year":"2017","journal-title":"Int. J. Pharm."},{"key":"B6","doi-asserted-by":"publisher","first-page":"105898","DOI":"10.1016\/j.jddst.2024.105898","article-title":"The potential role of hot flashes treatment strategies and regorafenib combinations in breast cancer therapy via co-drug loaded polymeric nanoparticles","volume":"98","author":"Esim","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1080\/21691401.2017.1347879","article-title":"Nano-encapsulated metformin-curcumin in PLGA\/PEG inhibits synergistically growth and hTERT gene expression in human breast cancer cells","volume":"46","author":"Farajzadeh","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1016\/0378-5173(89)90281-0","article-title":"Nanocapsule formation by interfacial polymer deposition following solvent displacement","volume":"55","author":"Fessi","year":"1989","journal-title":"Int. J. Pharm."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e187","DOI":"10.1002\/mco2.187","article-title":"Multifunctional nanoparticle for cancer therapy","volume":"4","author":"Gao","year":"2023","journal-title":"MedComm"},{"key":"B10","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3109\/21691401.2016.1160915","article-title":"Preparation and characterization of PLGA-\u03b2-CD polymeric nanoparticles containing methotrexate and evaluation of their effects on T47D cell line","volume":"45","author":"Gorjikhah","year":"2017","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.2147\/IJN.S241428","article-title":"Design, formulation and in vivo evaluation of novel honokiol-loaded PEGylated PLGA nanocapsules for treatment of breast cancer","volume":"15","author":"Haggag","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"B12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11095-019-2684-6","article-title":"Dual-targeted delivery of nanoparticles encapsulating paclitaxel and everolimus: a novel strategy to overcome breast cancer receptor heterogeneity","volume":"37","author":"Houdaihed","year":"2020","journal-title":"Pharm. Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1007\/s11033-022-08171-w","article-title":"Potentiation of folate-functionalized PLGA-PEG nanoparticles loaded with metformin for the treatment of breast cancer: possible clinical application","volume":"50","author":"Jafari-Gharabaghlou","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1080\/01635581.2019.1599968","article-title":"Synergistic antiproliferative effects of co-nanoencapsulated curcumin and chrysin on MDA-MB-231 breast cancer cells through upregulating miR-132 and miR-502c","volume":"71","author":"Javan","year":"2019","journal-title":"Nutr. Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2217\/nnm.11.19","article-title":"Nanoparticle PEGylation for imaging and therapy","volume":"6","author":"Jokerst","year":"2011","journal-title":"Nanomedicine (London)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S1470-2045(00)00254-0","article-title":"Epidemiology of breast cancer","volume":"2","author":"Key","year":"2001","journal-title":"Lancet Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"695","DOI":"10.3109\/21691401.2014.981270","article-title":"A comparison of the inhibitory effect of nano-encapsulated helenalin and free helenalin on telomerase gene expression in the breast cancer cell line, by real-time PCR","volume":"44","author":"Kordi","year":"2016","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"B18","volume-title":"WHO classification of tumours of the breast","author":"Lakhani","year":"2012"},{"key":"B19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jconrel.2008.04.024","article-title":"Super pH-sensitive multifunctional polymeric micelle for tumor pH(e) specific TAT exposure and multidrug resistance","volume":"129","author":"Lee","year":"2008","journal-title":"J. Control. Release"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1080\/10717544.2019.1669734","article-title":"Novel multifunctional triple folic acid, biotin and CD44 targeting pH-sensitive nano-actiniaes for breast cancer combinational therapy","volume":"26","author":"Liu","year":"2019","journal-title":"Drug Deliv."},{"key":"B21","doi-asserted-by":"publisher","first-page":"120847","DOI":"10.1016\/j.biomaterials.2021.120847","article-title":"Tumor hypoxia-activated combinatorial nanomedicine triggers systemic antitumor immunity to effectively eradicate advanced breast cancer","volume":"273","author":"Liu","year":"","journal-title":"Biomaterials"},{"key":"B22","doi-asserted-by":"publisher","first-page":"13350","DOI":"10.3390\/ijms222413350","article-title":"Cyclodextrin-containing hydrogels: a review of preparation method, drug delivery, and degradation behavior","volume":"22","author":"Liu","year":"","journal-title":"Int. J. Mol. Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41565-021-01032-w","article-title":"Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion","volume":"17","author":"Liu","year":"2022","journal-title":"Nat. Nanotechnol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/polym3031377","article-title":"Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier","volume":"3","author":"Makadia","year":"2011","journal-title":"Polymers (Basel)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0168-3659(02)00320-6","article-title":"A novel controlled release formulation for the anticancer drug paclitaxel (Taxol\u00ae): PLGA nanoparticles containing vitamin E TPGS","volume":"86","author":"Mu","year":"2003","journal-title":"J. Control. Release"},{"key":"B26","article-title":"Appendix F: quality appraisal checklist\u2014Quantitative intervention studies","volume-title":"Methods for the development of NICE public health guidance","year":"2012"},{"key":"B27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ijpharm.2005.10.010","article-title":"Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles","volume":"307","author":"Owens","year":"2006","journal-title":"Int. J. Pharm."},{"key":"B28","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1136\/bmj.n71","article-title":"PRISMA 2020 statement: an updated guideline for the publication of systematic reviews","volume":"74","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B29","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.nano.2011.05.016","article-title":"Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging","volume":"8","author":"Parveen","year":"2012","journal-title":"Nanomedicine"},{"key":"B30","doi-asserted-by":"publisher","first-page":"100248","DOI":"10.1016\/j.mtbio.2022.100248","article-title":"Peptide-based delivery of therapeutics in cancer treatment","volume":"14","author":"Samec","year":"2022","journal-title":"Mater. Today Bio."},{"key":"B31","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1038\/modpathol.2010.33","article-title":"Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy","volume":"23","author":"Schnitt","year":"2010","journal-title":"Mod. Pathol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11095-018-2555-6","article-title":"Anti-invasive and anti-proliferative effects of shRNA-loaded poly(lactide-co-glycolide) nanoparticles following RAN silencing in MDA-MB231 breast cancer cells","volume":"36","author":"Sharma","year":"2018","journal-title":"Pharm. Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1021\/nl102184c","article-title":"Nanotechnology in drug delivery and tissue engineering: from discovery to applications","volume":"10","author":"Shi","year":"2010","journal-title":"Nano Lett."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.3109\/03639045.2015.1019355","article-title":"Development and characterization of folate-anchored saquinavir entrapped PLGA nanoparticles for anti-tumor activity","volume":"41","author":"Singh","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"B35","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B36","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3109\/21691401.2014.955108","article-title":"A comparison between the cytotoxic effects of pure curcumin and curcumin-loaded PLGA-PEG nanoparticles on the MCF-7 human breast cancer cell line","volume":"44","author":"Tabatabaei Mirakabad","year":"2016","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"B37","unstructured":"Effectiveness of drug-loaded PEG-PLGA nanoparticles in cancer treatment: a systematic review. PROSPERO CRD420251076570\n          \n          \n            \n              V\u00e1squez\n              E.\n            \n            \n              Sandoval\n              C.\n            \n          \n          \n          2025"},{"key":"B38","doi-asserted-by":"publisher","first-page":"6961","DOI":"10.2147\/IJN.S174068","article-title":"Doxorubicin-loaded protease-activated near-infrared fluorescent polymeric nanoparticles for imaging and therapy of cancer","volume":"13","author":"Yildiz","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.3390\/polym15071596","article-title":"Nanoparticles as drug delivery systems: a review of the implication of nanoparticles' physicochemical properties on responses in biological systems","volume":"15","author":"Yusuf","year":"2023","journal-title":"Polymers"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1710176\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T07:25:20Z","timestamp":1767597920000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1710176\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":39,"alternative-id":["10.3389\/fphar.2025.1710176"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1710176","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"article-number":"1710176"}}